Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
- Neuropathic Pain
- Central Neuropathic Pain
- Clinical Study Report
- Alternative Investment Market
- Cannabis Extract
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Aldrich MR (1997) History of therapeutic cannabis. In: ML Mathre (ed.): Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. McFarland & Co., Inc. Jefferson NC, 28640; USA, 35–55
Russo EB (2001) Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther 1(2): 21–92
Russo EB (2002) Cannabis treatments in obstetrics and gynaecology: A historical review. J Cannabis Ther 2(3–4): 5–35
Grinspoon L, Bakalar JB (1993) History of the use of cannabis. In: Marihuana, the Forbidden Medicine. Yale University Press, New Haven, CT
The House of Lords Science and Technology Committee — Ninth Report 1998. Cannabis: the Scientific Evidence. HMG The Stationery Office, London, UK
Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. JAm Chem Soc 86: 1646–1647
Chan PC, Boorman GA, Bridge DA, Bucher JR, Elwell MR, Goehl TJ, Haseman JK, Rao GN, Roycroft JH, Sills RC et al. (1996) 1-Trans-Delta9-Tetrahydrocannabinol (Cas No. 1972-08-3): Studies of Toxicology and Carcinogenesis In F344/N Rats And B6c3fl Mice (Gavage Studies). U.S. Department of Health And Human Services, Public Health Service, National Institutes of Health (NIH) Technical Report Series No. NTP TR 446; NIH Publication No. 97-3362 (1996), Bethesda, MD
Joy JE, Watson SJ Jr, Benson JA Jr (eds) (1999) Marijuana and Medicine — Assessing the Science Base. Division of Neuroscience and Behavioral Health, Institute of Medicine National Academy of Sciences, National Academy Press, Washington, D.C
Beaver WT, Buring J, Goldstein A, Johnson K, Jones R, Kris MG, Mooney K, Palmberg P, Phair J (1997) NIH Report on the medical uses of marijuana, 08 August 1997. From the Workshop on the Medical Utility of Marijuana (19 and 20 Feb 1997) National Institutes of Health (NIH), Bethesda, MD
AMA Medical Marijuana (1997) Council on Scientific Affairs Report 10. Medical marijuana. American Medical Association, Interim Meeting, Dallas, TX, December 1997. http://www.ama-assn.org/ama/pub/article/2036-4299.html
(1997) Therapeutic Uses of Cannabis. BMA/Harwood Academic Publishers, Amsterdam
Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiat 178:101–106
Robson PJ (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiat 178: 107–115
Johns A (2001) Psychiatric aspects of cannabis use. Br J Psychiat 178: 116–122
Cannabis: The Scientific and Medical Evidence (11 November 1998) HM Government: House of Lords Science and Technology Select Committee Science and Technology Ninth Report (Session 1997–98). HL 151
Therapeutic Uses of Cannabis (21 March 2001) HM Government: House of Lords Science and Technology Select Committee Science and Technology Second Report (Session 2000–01). HL 50
Elphick M, Ergetova MR (2001) The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond B 356(1407): 381–408
Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35(17): 1803–1810
Howlett AC, Fleming MR (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26(3): 532–538
Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5): 605–613
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284): 561–564
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441): 61–65
GW Pharmaceuticals plc website www.gwpharm.com. Research and Development/Cannabis-based Medicines/Cannabinoids. http://www.gwpharm.com/research_cannabinoids.asp
Pertwee RG (1997) Pharmacology of CB1 and CB2 Receptors. Pharmacol Ther 74(2): 129–180
Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090): 1946–1949
Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83(3): 1017–1066
Hanuš L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98(7): 3662–3665
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3): 1020–1024
Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99(12):8400–8405
Millman G, Maor Y, Horowitz M, Gallily R, Hanug L, Mechoulam R (2004) Arachidonoyl-serine, an endocannabinoid-like bioactive constituent of rat brain. 2004 Symposium on the Cannabinoids, ICRS, Burlington, Vermont, ICRS, 133
McPartland J, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 1(3–4): 103–132
Russo EB, McPartland J (2003) Cannabis is more than simply delta-9-tetrahydrocannabinol. Psychopharmacology 165: 431–432
Mechoulam R, Ben-Zvi Z, Shani A, Zemler H, Levy S (2001) Cannabinoids and Cannabis activity. In: WDM Paton, J Crown (eds): Cannabis and its derivatives. Oxford University Press, London, 1–13
Carlini EA, Karniol IG, Renault PF, Schuster CR (1974) Effects of marihuana in laboratory animals and man. Brit J Pharmacol 50: 299–309
Fairbairn JW, Pickens JT (1981) Activity of cannabis in relation to its delta-l-trans-tetrahydro-cannabinol con tent. Brit J Pharmacol 72: 401–409
Grinspoon L, Bakalar JB (1997) Marihuana, the forbidden medicine, revised edition. Yale University Press, New Haven, CT
Browne RG, Weissman A (1981) Discriminative stimulus properties of delta-9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21(8–9 Suppl): 227S–234S
GW Pharmaceuticals plc. Clinical Study Report GWPKOOO8 (data on file)
McPartland J (2003) Neurobiological effects of cannabinoids. Lecture: American Academy of Pain Management (AAPM), 4 Sept 2003
Walton RP (1938) ((Title?)) In: Marihuana, America’s new drug problem. J.B. Lippincott Co., Philadelphia, USA, 49
Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol In: V Di Marzo (eds): Cannabinoids. Kluwer Academic/Plenum Publishers
Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription medicines. J Cannabis Ther 1(3–4): 183–205
Whittle BA, Guy GW (2004) Development of cannabis-based medicines: risk, benefit and serendipity. In: GW Guy, PJ Robson, BA Whittle (eds): The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press, London
European Medicines Evaluation Agency (EMEA). http://www.emea.eu.int/index/indexhl.htm
Food and Drug Administration (FDA) (2004) Guidance for Industry: Botanical Drug Products (June 2004) Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), FDA, Rockville, MD
Potter DJ (2004) Growth and morphology of medicinal cannabis. In: GW Guy, PJ Robson, BA Whittle (eds): The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press, London
Guy GW, Flint ME (2003) A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther 3(3): 35–77
Guy GW, Robson PJ (2003) A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112). J Cannabis Ther 3: 79–120
Guy GW, Robson PJ (2003) A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215). J Cannabis Ther 3: 121–152
Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 59(5): 440–452
Wade DT, Robson PJ, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17: 21–29
Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ and Fowler CJ (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10: 425–433
GW Pharmaceuticals — Study GWN19904 — Clinical Study Report (data on file)
GW Pharmaceuticals — Study GWCRI016 — Clinical Study Report (data on file)
Rog DJ, Young CA (2003) Randomised controlled trial of Cannabis Based Medicinal Extracts in central neuropathic pain due to multiple sclerosis. Abstracts of the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS, September 17–20, 2003, Milan, Italy). Mult Sclerosis 9(Suppl. 1): S1–S162
Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112: 299–306
Sharief MK (2004) Sativex® in the treatment of patients with chronic refractory pain due to MS or other defects of neurological function. Spring Scientific Meeting (2004) Association Of British Neurologists (14–16 April 2004, Church House, Westminster, London). Abstract.
Wade DT, Makela P, Robson PJ, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo controlled study on 160 patients. Mult Scler 10: 434–441
GW Pharmaceuticals plc — Study GWMS0106 — Clinical Study Report (data on file)
GW Pharmaceuticals plc — Study GWNP0101 — Clinical Study Report (data on file)
Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329: 253–260
Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults. J Clin Psychopharmacol 24(3): 305–313
Wade DT, Makela P, Robson PJ, House H, Bateman C (2005) Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler; submitted
GW Pharmaceuticals plc — Study GWEXT0102 — data on file
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Guy, G.W., Stott, C.G. (2005). The development of Sativex® — a natural cannabis-based medicine. In: Mechoulam, R. (eds) Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7358-X_14
Download citation
DOI: https://doi.org/10.1007/3-7643-7358-X_14
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7055-8
Online ISBN: 978-3-7643-7358-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)